Key Highlights

  • Arovella said first dosing in its ALA-101-001 first-in-human trial is expected in October 2026, with no patient yet dosed.
  • Two Manufacturing batches were manufactured and released for clinical use in September 2026.
  • Cash was A$11.60 million at 30 September 2026, with proforma cash of about A$15.63 million after a A$4.03 million R&D tax incentive rebate received in October.

Arovella Therapeutics Limited (ASX:ALA) said in its quarterly update for the period ended 30 September 2026 that its focus is ALA-101, a CD19-targeted CAR-iNKT cell therapy for blood cancers. The company said two manufacturing batches were manufactured and released for clinical use in September 2026, and that it believes they provide enough material to complete dose escalation and begin dose expansion. The ALA-101-001 study is a first-in-human dose-escalation and expansion trial in relapsed or refractory CD19-positive non-Hodgkin lymphoma and certain leukaemias.

The Alfred and Epworth Hospital sites were activated and began screening patients during the quarter, with two more sites being activated. First dosing is expected in October 2026, which the company called a major milestone. No patient has yet been dosed, so efficacy and safety in humans remain unproven.

Dosing rules and targets

Regulators require a 28-day wait between dosing the first three patients, and again before the first patient at each new dose level, and screening continues during these intervals. The study aims to assess safety and tolerability, determine a dose for further development, and generate early data on anti-tumour activity, expansion, persistence and CD19-positive B-cell depletion. By the end of the first quarter of calendar 2027 the company is targeting completion of dosing at the first dose level, the start of the second level and faster enrolment, with more sites expected to open after initial safety data. Arovella says its off-the-shelf approach avoids waiting for patient-specific manufacturing slots, which remains subject to clinical evaluation.

Solid tumour and autoimmune plans

ALA-105, an armoured CAR-iNKT therapy targeting CLDN18.2 in solid tumours, remains preclinical. In vivo animal study data are expected in the coming weeks and, the company said, would inform advancement towards the clinic through IND-enabling non-clinical and manufacturing work. For the rest of calendar 2026 the company also lists generating initial ALA-101 clinical data, including B-cell depletion, to support expansion into autoimmune disease, and preparing regulatory filings for ALA-101 in autoimmune disease. These are planned milestones and not approvals.

Finances

Cash was A$11.60 million at 30 September 2026, down from A$14.35 million at 30 June. Net operating outflow was A$2.73 million, including A$1.72 million for Research and Development and A$825,000 for staff, and no Equity was raised. The company said proforma cash was about A$15.63 million after an FY26 research and development tax incentive rebate of A$4.03 million that was received in October 2026. The Appendix 4C estimates 4.2 quarters of funding on the quarter's outflow, which the company said will move as trial spending develops. The company has no Debt or financing facilities.

Developments elsewhere and caveats

Arovella pointed to developments elsewhere. BrightPath Biotherapeutics received US FDA clearance for an iPSC-derived CAR-iNKT therapy aimed at BCMA in multiple myeloma, and Adicet Bio reported phase 1 results for a CD20-directed gamma-delta CAR-T therapy in lupus. The company also noted that Novartis and Bristol Myers Squibb paused or halted certain autoimmune studies of autologous CAR-T products after safety events. These relate to different products and targets.

The company states that potency, safety, tumour-targeting, cost and access advantages of its approach remain subject to clinical evaluation and manufacturing and economic validation. Executives presented at investor events including the Cell and Gene Meeting on the Mesa in Phoenix in October, and an investor webinar was held in August.

Upcoming milestones

The milestones listed by Arovella Therapeutics (ASX:ALA) are first patient dosing in October 2026, the ALA-105 animal data in the coming weeks and, by the end of the first quarter of 2027, completion of the first dose level. Each is a company expectation, and the dosing requirements are staggered as described above.